Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics Expands Maine Facility, Boosts Antibody Production by Half

NEW YORK (GenomeWeb News) - Strategic Diagnostics has expanded its antibody-production facility in Windham, Maine, the company said Tuesday.
 
The Newark, Del.-based company said the newly added 15,000-square-foot space, which will begin operating in mid-November, will allow it to boost polyclonal antibody production by 44 percent.
 
Strategic Diagnostics said the extra capacity will enable it to meet “surging” demand for its Genomic Antibody Technology platform and to support the recent launch of its web-based catalog of oncology-focused antibody reagents.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.